Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Hims & Hers Health: GLP-1 Deals De-Risk The Story
03:27pm, Tuesday, 29'th Apr 2025
Hims & Hers Health partners with Novo Nordisk to offer Wegovy, de-risking investment but not significantly altering the business focus on personalized healthcare solutions. The health and wellness pla
BURLINGTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root
Global Partners Declares First-Quarter 2025 Cash Distribution of $0.7450 on Common Units
08:30am, Friday, 25'th Apr 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has
Global Partners LP to Host First-Quarter 2025 Financial Results Conference Call on May 8, 2025
08:30am, Thursday, 24'th Apr 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its first-quarter 2025 financial results before th
Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
11:21am, Wednesday, 23'rd Apr 2025
Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business, presenting a buying opportunity for long-term investors. The company is ramping up liraglutide manufactur
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology
09:10am, Wednesday, 23'rd Apr 2025
Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry Lexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, 2
Eli Lilly Nails Oral GLP-1 Trial—Here's What It Means for LLY
07:33am, Wednesday, 23'rd Apr 2025
The world's largest pharmaceutical stock, Eli Lilly and Company NYSE: LLY, is back in the green in 2025 as of the Apr. 21 close. Shares were down moderately in 2025 through mid-April.
- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg , an
A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
06:20am, Sunday, 20'th Apr 2025
Drugmaker Eli Lilly (LLY 14.56%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the firs
Eli Lilly jumps on GLP-1 pill trial success
06:17pm, Thursday, 17'th Apr 2025
CNBC's Angelica Peebles joins 'Fast Money' to talk the latest on oral GLP-1 trials.
Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results
01:45pm, Thursday, 17'th Apr 2025
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages over co
Lilly reports positive phase 3 trial results for GLP-1 pill
10:29am, Thursday, 17'th Apr 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest results from Eli Lilly's efforts to develop a GLP-1 pill.
Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars
07:58am, Thursday, 17'th Apr 2025
Eli Lilly And Co LLY stock is trading higher on Thursday after the U.S. healthcare giant reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2
